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Bladder lymphomas are rarely primary tumours and more commonly associated with systemic lymphoma, either as nonlocalised
bladder lymphoma or as secondary bladder lymphoma. Primary bladder lymphomas (PBL) tend to be low-grade mucosa-
associated lymphoid tissue (MALT) type, contrasting with diﬀuse large cell or follicular centre cell types more commonly seen
in secondary bladder lymphoma. Bladder involvement by systemic lymphoma infers poor prognosis and patients often have no
localising symptoms (typically a postmortem diagnosis). Other treatments are preferred over surgery for all bladder lymphomas,
except where diagnosis is uncertain or for relief of irritative bladder symptoms. We describe a unique case of systemic high-grade
B-cell lymphoma with simultaneous cutaneous renal and bladder lesions at presentation.
1. Case Report
A 70-year-old man presented to the dermatologists with a 2-
year history of painless enlarging scalp nodules, which had
rapidly worsened over the previous 6 months (Figure 1(a)).
He had lost 7 kg in weight; there were no other systemic
symptoms. He had neither clinical lymphadenopathy nor
hepatosplenomegaly and his peripheral blood count, ESR,
protein electrophoresis, liver function tests, and LDH were
normal. A skin biopsy from the scalp demonstrated high-
grade B-cell non-Hodgkin’s lymphoma. Staging CT showed
multiple small cervical lymphadenopathy, lymphomatous
infiltration in both kidneys, and an area of mucosal thick-
ening of the bladder, which was consistent with a primary
bladder carcinoma. Staging was completed with an MRI of
the head (Figure 1(b)) and bone marrow biopsy, which was
normal.
The patient described neither lower urinary tract symp-
toms nor episodes of macroscopic haematuria and was a
nonsmoker. A urine cytology specimen revealed atypical cells
more consistent with lymphoid than epithelial/transitional
cell origin (Figure 2(a)). At cystoscopy, a 3 cm round
submucosal lesion on the anterior aspect of the bladder
wall was seen and resected. Histology confirmed high-
grade B-cell lymphoma in both bladder and kidney biopsies
(Figure 2(b)).
2. Discussion
To date there are few case reports of nonprimary bladder
lymphoma, reflecting its rarity as a presenting pathological
entity. To our knowledge we describe the first reported case
of disseminated lymphoma with simultaneous cutaneous,
renal, and bladder lesions demonstrable at presentation.
The incidence of non-Hodgkin’s lymphoma (NHL) is
increasing and maintains a geographical variability: in 2007
there were 10,900 people diagnosed with NHL in the UK
[1]. The incidence of NHL typically increases with age. Rates
increase sharply in people over 50 and around two-thirds
(68%) of all cases are diagnosed in people over 60 years.
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Figure 1: (a) Scalp nodules as seen at presentation. (b) MRI demonstrating an extensive mixed signal, soft tissue mass, over the vertex of the
skull. There is infiltration through the inner and outer tables of the skull vault and extension into the dural membranes.
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Figure 2: (a) Urine cytology demonstrates a cluster of atypical lymphoid cells. (b) Biopsy of bladder tumour showing infiltration of the
transitional epithelium and lamina propria by atypical B lymphocytes (CD20 positive on immunohistochemistry).
The most recent classification system is that endorsed by
the World Health Organisation (REAL classification) and
includes subtypes such as diﬀuse large B-cell, follicular,
and small lymphocytic. Determinations of specific subtypes
of disease along with patient’s prognostic characteristics
gleaned from the International Prognostic Index are crucial
to treatment plans and subsequent management.
Lymphomas of the bladder are rare and account for 0.2%
of all bladder neoplasms [2]. There is a female predominance
and average age of presentation of 58 years. The most
common type is extranodal marginal zone lymphoma of
mucosal-associated lymphoid tissue (MALT) first described
in 1990 [3], while Hodgkin’s type is even rarer. Lymphomas
are classed into the primary group if they present primarily
with bladder symptoms and there is no evidence of systemic
lymphoma at presentation.
More commonly, although relatively few case studies
exist, lymphoma of the bladder is seen in association
with systemic lymphoma; this can either be as bladder
involvement with active systemic lymphoma (nonlocalised
bladder lymphoma), as reported in this case study, or as
lymphoma recurrence in the bladder after a period of
remission from previous lymphoma (secondary lymphoma)
[3]. It is rare for disseminated lymphoma to present
with symptoms of bladder involvement and more typically
remains a postmortem diagnosis [2]. Although a percentage
of patients with bladder involvement experience no urinary
symptoms, urinary urgency, frequency, and haematuria have
all been described [3]. It has been reported that a high
proportion (47%) of patients in this group experience
ureteric obstruction [3].
Nonprimary bladder lymphomas tend to be a dif-
ferent histological type than those found in the PBL
group and are commonly of the diﬀuse large cell or
follicular centre cell types [3]. In the nonprimary group,
the bladder involvement by systemic lymphoma infers a
poorer prognosis than that seen in PBL as it implies
multisystem disease. However, there is a clear prognostic
distinction between the secondary bladder lymphoma and
non-localised lymphoma groups with median survival of
0.6 years and 9 years, respectively [3]. Part of this might
be explained by some patients being classified in the non-
localised group when a dominant bladder mass was only
associated with local extension to adjacent organs or to
regional lymph nodes [3]. The authors argued that although
some might classify this category of patient into a “PBL”
group, their tumour histology resembled more closely that
of the general population and the patient and disease
characteristics were distinct from those seen in the PBL
group [3].
Non-Hodgkin’s lymphoma involving the bladder can
be successfully treated using chemotherapy, radiotherapy,
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immunotherapy, surgery, and combinations of these modal-
ities [4]. The treatment of choice is determined by the
histology and extent of disease. The systemic nature of non-
primary bladder lymphoma warrants a systemic approach to
treatment. Lymphomas with aggressive phenotypes such as
diﬀuse large B-cell are best managed with chemotherapy. The
cyclophosphamide, doxorubicin, vincristine, prednisone,
and rituximab (CHOP/R) regime is most commonly used
[4]. Adjuvant radiotherapy is used for involved fields in
localised disease. Follicular lymphoma treatments range
from a watch-and-wait policy to chemoimmunotherapy or
radioimmunotherapy. Immunotherapy generally forms a
standard component of management of advanced disease
[4].
The indolent nature of theMALT lymphomas means that
local radiotherapy can be used with curative intent, such
as in PBL. Surgical resection has a limited role in primary
bladder lymphoma, beyond obtaining biopsy specimens, and
rarely adds anything to management or prognosis. There are
reports, however, of patients having undergone cystectomy
due to unclear diagnosis, or to relieve irritative symptoms
[5]. There is a report of a low-grade MALT-type PBL
being managed with transurethral resection and adjuvant
intravesical mitoxantrone [6].
In this case, the patient’s disease constituted stage IV
B. He underwent eight cycles of CHOP/R chemotherapy
followed by radical radiotherapy to scalp and brain. Follow-
up MRI showed dramatic improvement in the scalp and
dural mass with minimal residual dural enhancement. A
repeat CT showed complete remission with no residual
disease in either kidneys or bladder. The patient remained
in complete remission for 14 months but then developed a
gradual deterioration in his balance and thereafter a marked
peripheral neuropathy. Repeat imaging confirmed recurrent
widespread cerebral metastasis. He died following a cardiac
arrest before palliative radiotherapy could be given.
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